Skip to main content
SpringerLink
Log in

Metastasierter Brustkrebs: Metronomes Cyclophosphamid ergänzt die Therapie

  • Gynäkoonkologie
  • Literatur kompakt
  • Published:
Im Focus Onkologie Aims and scope

Ältere Patientinnen mit HER2-positivem, metastasiertem Brustkrebs, die zusätzlich zu Pertuzumab und Trastuzumab noch eine metronome Chemotherapie mit Cyclophosphamid erhalten, bleiben länger von einem Fortschreiten des Tumors verschont.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Wildiers H et al. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Lancet Oncol. 2018;19(3):323–36.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Robert Bublak

  2. Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Köln, Köln, Deutschland

    Peter Mallmann

Authors
  1. Robert Bublak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Mallmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Mallmann.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bublak, R., Mallmann, P. Metastasierter Brustkrebs: Metronomes Cyclophosphamid ergänzt die Therapie. Im Focus Onkologie 21, 13–14 (2018). https://doi.org/10.1007/s15015-018-4019-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-018-4019-6

Search

Navigation